Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by biggdoggon Nov 21, 2024 6:16pm
59 Views
Post# 36324912

Market to double next 8 yrs

Market to double next 8 yrsThe market for contrast media is experiencing rapid growth at a rate of 7.4% and is expected to double within the next 8 years, reaching $12 billion. Voyageur is poised to benefit from this long-term bull market. This growth is crucial for their drug development initiatives, particularly as the potential value of new drugs successfully transitioning past phase one trials is expected to be substantially higher than other drugs, as value is based on market size. Additionally, the projected doubling of the barium market further underscores the significance of this growth trend, with a 7.4% growth rate representing a considerably high rate of expansion.
In the context of pharmaceutical consumables, a 7.4% growth rate is generally considered significant and relatively high. Pharmaceutical markets often have more modest growth rates compared to other industries, making a 7.4% growth rate notably high. This rate of growth indicates increasing demand, market expansion, and potentially lucrative opportunities for Voyageur.
The critical minerals required for contrast media will never keep up to demand at this rate. Why anyone would sell this stock is mind blowing.
https://www.gminsights.com/industry-analysis/contrast-media-market

<< Previous
Bullboard Posts